A dip before financials has occurred each time, only to go up after the filings were disclosed. The extension on funding was huge news and really takes a lot of the risk out of the 4th quarter filings. I would say everything has been priced in and once the financials are revealed to be nothing outside of expectations or slightly better, you can expect this to price in the last two big news items rather quickly. Funding extension and yet another Phase 2 trial are big ticket items and yet we lost around .80 after the announcements.
The contrary point of view would say these were already priced in thus why we saw nearly $7.
News 
Market Data 
Discover 
